



**CERTIFICATE OF MAILING
UNDER 37 CFR 1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, P.O. Box 1450, Alexandria, VA 22313-1450 on 14 December 2010

HUESCHEN AND SAGE

Thomas A. Weiland

14 December 2010

Applicants : BIGALKE, et al.
Serial No. : 10/018,373
Filed : 06 December 2001
Title : THERAPEUTIC COMPOSITION COMPRISING A BOTULINUM NEUROTOXIN.
Art Unit : 1645

Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**COMMUNICATION COVERING TRANSMITTAL OF REQUEST FOR CONTINUED
EXAMINATION UNDER 37 CFR § 1.114 AND INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.97 AND 1.98**

Sir:

Herewith, in accord with the foregoing regulations, please find an Information Disclosure Statement which, it is respectfully submitted, should materially advance and accelerate the prosecution of the above-identified application. Attached hereto is a Form PTO/SB/08a and copies of the non-US patent/application documents and non-patent literature listed thereon. English language abstracts are provided for foreign language patent document(s) which are not available as US patent/application equivalents.

Moreover, Applicant has listed communications from patent proceedings with regard to International equivalents of the instant application. Copies of these communications are attached. Applicant makes no representation regarding the materiality of these communications to the claims currently pending in the instant application. Applicant lists these communications in this Information Disclosure Statement in an overabundance of caution and in observance of the holdings of Dayco Products Inc. v. Total Containment, Inc., 66 USPQ2d 1801 (Fed.Cir.2003), and McKesson Information Solutions, Inc. v. Bridge Medical, Inc., 82 USPQ2d 1865 (Fed.Cir.2007).

As will be noted, this Information Disclosure Statement calls a number of references, which might be considered relevant, to the attention of the Office. The fact that these are in fact "Prior Art" and/or relevant to the prosecution is, however, not admitted. In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is understood that, during examination, the Office will make an independent search and will identify

12/20/2010 EHAILE 00000037 10018373

02 FC:1806

100.00 0P

any relevant prior art under 37.CFR § 1.104(a). Entry of this Information Disclosure Statement into the file of this application, initialing of each reference entry, making all of the references called to the Office's attention therein of record, listing such references among the "References Cited" on any patent to issue therefrom, and favorable action on the merits of this application are all respectfully solicited.

Respectfully submitted,

THE FIRM OF HUESCHEN AND SAGE


Katherine L. WEILAND #56,942

Dated : 14 December 2010

Customer No. : 25,666

Seventh Floor, Kalamazoo Building

107 West Michigan Avenue

Kalamazoo, MI 49007

(269) 382-0030

Enclosure(s) : Request for Continued Examination, duplicate copy, and Fee; Form
PTO/SB/08a and Accompanying References and Fee; a check in the amount of
\$990.00 and Return Postal Card Receipt.

* * * * *

THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY FURTHER OR ADDITIONAL FEES WHICH MAY BE REQUIRED (DUE TO OMISSION, DEFICIENCY, OR OTHERWISE), OR TO CREDIT ANY OVERPAYMENT, TO DEPOSIT ACCOUNT NO. 08,3220